| Autor: |
Vanderniet, Joel A, Szymczuk, Vivian, Högler, Wolfgang, Beck-Nielsen, Signe S, Uday, Suma, Merchant, Nadia, Crane, Janet L, Ward, Leanne M, Boyce, Alison M, Munns, Craig F |
| Předmět: |
|
| Zdroj: |
Journal of Clinical Endocrinology & Metabolism; May2024, Vol. 109 Issue 5, p1371-1382, 12p |
| Abstrakt: |
Context Denosumab is an effective treatment for many receptor activator of nuclear factor kappa-B ligand (RANKL)-mediated disorders but there are potential safety considerations and limited data to guide its use in children and adolescents. Objective This document seeks to summarize the evidence and provide expert opinion on safe and appropriate use of denosumab in pediatric RANKL-mediated disorders. Participants Ten experts in pediatric bone and mineral medicine from 6 countries with experience in the use of denosumab participated in the creation of this document. Evidence Data were sourced from the published literature, primarily consisting of case reports/series and review articles because of the lack of higher level evidence. Expert opinion of the authors was used substantially when no published data were available. Conclusion Denosumab is an effective treatment for RANKL-mediated disorders in children and adolescents but is often not curative and, in some cases, is best used in conjunction with surgical or other medical treatments. Careful multidisciplinary planning is required to define the goals of treatment and expert oversight needed to manage the risk of mineral abnormalities. Substantive, collaborative research efforts are needed to determine optimal treatment regimens and minimize risks. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
